Deprenyl Animal Health Inc. on Tuesday said it has entered intoa cooperative research and development agreement (CRADA)with Inhalation Toxicology Research Institute (ITRI) toevaluate the effects of the drug deprenyl on variousphysiologic functions during aging in dogs.
Trials are expected to start this month, according to Deprenyl.
The Overland Park, Kan., company (NASDAQ:DAHI) hascommitted about $1 million over the course of the five-yearagreement and will retain all rights to pre-existing patentapplications covering work under the project.
ITRI is operated for the U.S. Department of Energy by theLovelace Biomedical and Environmental Research Institute Inc.of Albuquerque, N.M. It is committing resources on a payment-in-kind basis.
(c) 1997 American Health Consultants. All rights reserved.